Rosetta's miR-451 could enhance Gleevec in brain tumours
This article was originally published in Clinica
One of Rosetta Genomics' microRNAs, miR-451, has been shown in vitro to inhibit cell growth of glioblastoma, the most common and aggressive form of primary brain tumour. When combined with Novartis's anticancer drug Gleevec (imatinib mesilate, also known as Glivec), a synergistic effect inhibiting glioblastoma cell proliferation was seen. Gleevec is a tyrosine kinase inhibitor that is used in certain leukaemias and gastrointestinal stromal tumours, as well as brain tumours. The study will be published in the November issue of Biochemical and Biophysical Research Communications.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.